Friday, August 07, 2015 5:36:12 PM
Company PRed about 33 in total at the start of Ph III.
If 17 at Overlook are open nGBM patients.
Ph II Blinded study was confirmed to be at 11 near the end of 2008. That leaves 5 unaccounted ones will be part of the open trial. I see those 5 being randomized into the open arm.
The more of those numbers are open the better the phii trial is going on enrollment as of 2012 in my opinion.
If it is 22, open nGBM from the Germany data only 14 will be vaccine like patients. (The control ones safety data would not be given to Germany.)
Now, as of 2012, Germany had received safety data on 73 ph III patients (overall open + blind study). If only 22 are open (again those randomized to SoC would be 7 control dropped - no safety on SOC patients) around 2/3 only would contributes to safety data on the entire Trial, so roughly 14 or 22. That leaves about 60 left from the Ph III blinded portion study to account for with enrollment into safety. On the blind portion of the study, placebo patient safety data will go to Germany with the group.
The rapids compassionate arm started in May 2008. Any pulled from the study, would come from the blinded enrolled number of 11 enrolled patients. I see that they don't include rapid data in their safety. So drop 1/3, if 7 were true nGBM; 4 Rapids. Germany only gets the safety on GBM not Rapids, as Rapids were not part of German study.
73 safety overall- 14 open vaccine patients = 59 safety from blinded only.
59 - 7 from pre-suspension = 52 post enrolled.
52 enrolled by Mid-2012 (restart only nGBM patients).
Easily they could added another 75 patients. They PRed in 2013 that they'd average about 25+ a quarter (they deleted that PR so it will likely be less). But over 6 quarters even if it's 15 a quarter that's not bad. (My account removed Rapids.)
So 7 enrolled (pre suspension) + 52 (2011- 2012) and ? (Mid 2012-2013 ).
7 + 52+ ? (enrollment from mid-2012-December 2013) patients= #? of enrolled patients.
66 events from that total.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM